anti-albuminuric effect of 1ow-dose spironolactone in patients with diabetic nephropathy
- Conditions
- diabetic nephropathy
- Registration Number
- JPRN-UMIN000022999
- Lead Sponsor
- Diabetes, Endocrinology and Metabolism, Shinshu University Hospital
- Brief Summary
The spironolactone group showed a significant reduction in UACR from baseline compared with the control group which showed an increased UACR (p = 0.0007, Wilcoxon rank-sum test and t-test). Although the spironolactone group had a statistically significant increase in serum potassium levels, none of the participants had a potassium level >5.5 mEq/L at 24 weeks. Further, participants with a higher initial serum potassium level tended to have a smaller increase (estimate -0.37, analysis of covariance).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 130
Not provided
1.eGFR less than 30mL/min/1.73m2 2.patients with potassium more than 5.0mEq/l 3.patients who have already treated with spironolactone 4.patients who have an allergy career to a study drug 5.pregnant woman and the woman whom I am nursing 6.other conditions that are considered inappropriate to participate by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction in the rate of albuminuria at 24 weeks after administration.
- Secondary Outcome Measures
Name Time Method